Tanvex BioPharma, Inc.
TWSE:6541.TW
61.8 (TWD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 61.411 | 22.404 | 5.406 | 0.3 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 326.543 | 41.752 | 1.856 | 0.157 | 215.964 | 142.768 | 132.705 | 117.575 | 67.382 | 0 | 0 |
| Gross Profit
| -265.132 | -19.348 | 3.55 | 0.143 | -215.964 | -142.768 | -132.705 | -117.575 | -67.382 | 0 | 0 |
| Gross Profit Ratio
| -4.317 | -0.864 | 0.657 | 0.477 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 1,381.914 | 1,351.425 | 1,383.521 | 1,860.6 | 2,000.112 | 1,652.837 | 1,084.425 | 1,107.989 | 662.197 | 340.557 | 215.514 |
| General & Administrative Expenses
| 404.292 | 208.754 | 176.784 | 209.043 | 259.566 | 261.93 | 308.202 | 243.529 | 169.755 | 124.34 | 85.833 |
| Selling & Marketing Expenses
| 49.416 | 25.99 | 42.429 | 30.077 | 68.478 | 35.813 | 10.541 | 0 | 0 | 0 | 0 |
| SG&A
| 453.704 | 234.744 | 219.213 | 239.12 | 328.044 | 297.743 | 318.743 | 243.529 | 169.755 | 124.34 | 85.833 |
| Other Expenses
| -7.579 | 9.533 | 99.073 | -4.72 | 69.535 | 56.742 | -6.607 | 107.098 | -3.278 | -1.317 | 2.339 |
| Operating Expenses
| 1,835.618 | 1,586.169 | 1,602.734 | 2,099.72 | 2,328.156 | 1,950.58 | 1,403.168 | 1,351.518 | 831.952 | 464.897 | 301.347 |
| Operating Income
| -2,100.75 | -1,586.387 | -1,496.967 | -2,085.642 | -2,258.621 | -1,950.58 | -1,403.168 | -1,351.518 | -831.952 | -464.897 | -301.347 |
| Operating Income Ratio
| -34.208 | -70.808 | -276.908 | -6,952.14 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -35.923 | -54.72 | -46.222 | -18.57 | -15.58 | 56.742 | -6.607 | 107.098 | -3.278 | -7.564 | 2.339 |
| Income Before Tax
| -2,136.673 | -1,641.107 | -1,543.189 | -2,104.212 | -2,274.201 | -1,893.838 | -1,409.775 | -1,244.42 | -835.23 | -472.461 | -299.008 |
| Income Before Tax Ratio
| -34.793 | -73.251 | -285.459 | -7,014.04 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0.428 | 0.023 | 0.022 | 0.024 | 0.025 | 0.024 | 0.025 | 0.026 | 0.025 | 0.024 | 0.024 |
| Net Income
| -2,137.101 | -1,641.13 | -1,543.211 | -2,104.236 | -2,274.226 | -1,893.862 | -1,409.8 | -1,244.446 | -835.255 | -472.485 | -299.032 |
| Net Income Ratio
| -34.8 | -73.252 | -285.463 | -7,014.12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -16.42 | -13.55 | -13.8 | -22.61 | -26.16 | -24.94 | -20.66 | -18.55 | -16.72 | -13.58 | -9.94 |
| EPS Diluted
| -16.42 | -13.55 | -13.8 | -22.61 | -26.16 | -23.72 | -20.66 | -18.55 | -16.72 | -13.58 | -9.94 |
| EBITDA
| -1,775.917 | -1,304.828 | -1,253.385 | -1,865.235 | -2,042.657 | -1,807.812 | -1,270.463 | -1,233.943 | -767.848 | -426.038 | -275.691 |
| EBITDA Ratio
| -28.919 | -58.241 | -231.851 | -6,217.45 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |